Synchrony Medical, creator of the FDA-cleared LibAirty Airway Clearance System, today announced it has closed an oversubscribed $5 million funding round. The investment will accelerate U.S. commercial expansion, support ongoing clinical research and product development, and broaden patient access to LibAirty.
For millions living with chronic lung conditions, airway clearance is essential to managing symptoms, preventing infections, and slowing disease progression. The LibAirty system delivers this therapy through a daily home treatment that has shown the ability to clear twice as much sputum as conventional therapies.
"This funding enables us to advance our mission of delivering meaningful clinical outcomes by bringing effective, easy-to-use airway clearance into more homes and empowering patients to manage their respiratory health," said Anat Shani, CEO of Synchrony Medical. "Supported by our exceptional investors and new board members, we're well positioned to scale our U.S. market presence, expand our clinical evidence base, and advance product innovation."
Synchrony will continue to expand its U.S. team and operations from its Jersey City headquarters. The financing includes $1 million funding from the NJEDA through the New Jersey Innovation Evergreen Fund (NJIEF)'s co-investment with Edge Medical Ventures, further supporting the company's growth and presence in the state.
